Ocugen said today that it launched a Phase III trial designed to evaluate its twice-daily 0.2% brimonidine tartrate eye drop in patients with dry eye disease.
Ocugen plans to run two identical Phase III trials of OCU310, enrolling 240 participants per study. The company said it will assess safety and efficacy results after just 28 days of treatment, due to the early potential therapeutic benefits of brimonidine tartrate that Ocugen observed in the Phase II study.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocugen kicks off dry eye disease trial for nanoemulsion eye drop appeared first on MassDevice.